



Structure and function of the *Nppa–Nppb* cluster locus during heart development and disease

Joyce Man¹ · Phil Barnett¹ · Vincent M. Christoffels¹

Received: 4 September 2017 / Revised: 7 December 2017 / Accepted: 20 December 2017 / Published online: 4 January 2018
© The Author(s) 2018. This article is an open access publication

Abstract

Atrial natriuretic factor and brain natriuretic peptide are two important biomarkers in clinical cardiology. These two natriuretic peptide hormones are encoded by the paralogous genes *Nppa* and *Nppb*, which are evolutionary conserved. Both genes are predominantly expressed by the heart muscle during the embryonic and fetal stages, and in particular *Nppa* expression is strongly reduced in the ventricles after birth. Upon cardiac stress, *Nppa* and *Nppb* are strongly upregulated in the ventricular myocardium. Much is known about the molecular and physiological cues inducing *Nppa* and *Nppb* expression; however, the transcriptional regulatory mechanisms of the *Nppa–Nppb* cluster in vivo has proven to be quite complex and is not well understood. In this review, we will provide recent insights into the dynamic and complex regulation of *Nppa* and *Nppb* during heart development and hypertrophy, and the association of this gene cluster with the cardiomyocyte-intrinsic program of heart regeneration.

Keywords Atrial and brain natriuretic peptide · Epigenetics · Gene cluster · Heart development · Heart regeneration · Hypertrophy · Super enhancer

Abbreviations

ANF	Atrial natriuretic factor
BAC	Bacterial artificial chromosome
BNF	Brain natriuretic peptide
BZ	Border zone
CTCF	CCCTC-binding factor
Irx	Iroquois
PE	Phenylephrine
Pol II	RNA polymerase II
TADs	Topologically associated domains

Introduction

Pathological stress in the heart results in physiological changes accompanied by alterations at both the transcriptional and epigenetic level. These stresses include cardiac hypertrophy and ischemic injury (myocardial infarction). During hypertrophy, the myocardium undergoes adverse structural remodeling that can lead to heart failure, the heart being unable to meet the circulatory demands of the body [1]. Myocardial infarction leads to loss of muscle mass, scar formation and compensatory hypertrophy [2]. A commonly observed response during cardiac hypertrophy is reactivation of the “fetal gene program”. Normally, these fetal genes are abundantly expressed in the prenatal heart but become downregulated after birth. Once the heart undergoes pathological stress, the expression of these genes is induced and this response is thought to play a role in the process of cardiac remodeling and compensation [3–6]. The induction, however, may be orchestrated by a stress-induced regulatory mechanism different to that of the developmental regulatory program [7, 8].

Nppa and *Nppb*, cardiac genes encoding atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP), respectively, belong to this fetal gene program. Both genes are abundantly expressed in the atrial and ventricular

✉ Joyce Man
j.c.man@amc.uva.nl
Phil Barnett
p.barnett@amc.uva.nl
Vincent M. Christoffels
v.m.christoffels@amc.uva.nl

¹ Department of Medical Biology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands

myocardium during embryonic and fetal stages. After birth, both genes remain expressed in the heart, however, postnatal expression of *Nppa* is strongly downregulated in the ventricles [9–11]. Upon stress, the pro-peptides are released by the heart and the ventricular expression of both *Nppa* and *Nppb* is strongly increased in the cardiomyocytes [12, 13]. Because of this feature, the gene products, especially NT-pro-BNP that has a longer half-life compared to BNP and ANF, serve as reliable molecular markers to assess cardiac disease and heart failure progression [14, 15]. Additionally, *Nppa* has also become an important marker for myocardial chamber differentiation and congenital heart defects [16, 17]. The importance of *Nppa* and *Nppb* in heart development and disease has initiated in-depth studies on the transcriptional regulatory mechanisms of these genes. Insights into these mechanisms have already substantially increased our understanding of the molecular events underlying heart development and pathological stress of the heart [18].

The paralogous genes *Nppa* and *Nppb* are positioned in close proximity to each other and organized in an evolutionary conserved gene cluster [19–21]. The structural organization and regulation of *Nppa* and *Nppb* expression have proven to be more complex than was initially thought [7, 8, 22–24]. Therefore, the identification and functional analysis of regulatory sequences of the *Nppa*–*Nppb* cluster has been challenging. Nevertheless, current genomic technologies applied to study epigenetic landscapes, chromatin structure and gene regulation (e.g. chromatin immunoprecipitation sequencing and chromatin conformation capturing combined with transgenic reporter mice) has shed light on the regulatory mechanisms of the *Nppa*–*Nppb* cluster in vivo [8, 13, 23, 24]. In this review, we will discuss recent progress in deciphering the regulatory landscape of the *Nppa*–*Nppb* cluster during heart development and disease.

Gene clusters: conceptual framework of sharing and co-regulation

The spatial and temporal pattern of gene expression is regulated through *cis*-regulatory DNA elements (e.g. promoters, enhancers, insulators, repressors) that function in strictly context-dependent manners. The transcriptional machinery that drives cell-specific gene expression involves the binding of transcription factors and co-factors at specific locations on the DNA via sequence-dependent affinity. This process is coordinated by epigenetic motifs and signatures, and the three-dimensional arrangement of chromatin, which is responsible for bringing necessary components in spatial proximity [18, 25–27]. During evolution, the natriuretic peptide genes *Nppa* and *Nppb* have arisen from the ancestral CNP-3 gene through the process of gene duplication followed by divergence [28]. *Nppa* and *Nppb* are positioned

in close proximity to each other in the mammalian genome, separated by only several kilo base pairs (kbp) of DNA sequence. Comparative studies have demonstrated that these paralogous genes show very similar expression patterns in the developing atrial and ventricular chamber myocardium of mouse, rat and human. In contrast, birds have lost the *Nppa* gene, and their *Nppb* gene is expressed at high levels in both atria and ventricles [9, 29]. Both *Nppa* and *Nppb* are upregulated in response to hypertrophy [30] and in the injury border zone after myocardial infarction [13]. These common features of *Nppa* and *Nppb* suggest that this gene cluster may contain *cis*-regulatory sequences shared by both genes, and a topology that facilitates co-regulation during development and stress. Sharing of regulatory sequences and co-regulation of clustered paralogous genes has been proposed previously; however, to date only few examples have been comprehensively described, including the *Iroquois* (*Irx*) and *Hox* gene clusters.

The *Irx* gene cluster is present in both invertebrates and vertebrates. In mammals, the *Irx* genes are divided into two paralogous clusters, *IrxA* (*Irx1*, *Irx2* and *Irx4*) and *IrxB* (*Irx3*, *Irx5* and *Irx6*), located on different chromosomes [31]. In both clusters, the orientation of the three genes is strictly conserved and organized. The developmental expression patterns of clustered genes *Irx1* and *Irx2*, and of *Irx3* and *Irx5*, respectively, are highly similar [32]. All six genes are expressed in specific patterns in the heart, and *Irx3*, 4 and 5 are involved in cardiac development and conduction [33, 34]. Extensive screening of the genomic regions of the *IrxA* and *IrxB* cluster revealed highly conserved non-coding regions with *cis*-regulatory elements. These *cis*-regulatory elements physically interact with the promoters of the first two genes of the *Irx* gene clusters. Furthermore, *Irx1/Irx2* and *Irx3/Irx5* are engaged in promoter–promoter interaction and this explains why their expression patterns overlap during development. The third genes *Irx4* and *Irx6*, respectively, do not seem to interact with the other two genes of their cluster or their shared regulatory elements and consistently show distinct expression patterns [35].

Hox genes play a crucial role in vertebrate anterior–posterior patterning and limb development [36–38]. In mammals, 39 *Hox* genes are found organized in four genomic clusters (*HoxA*, *B*, *C* and *D*) that are localized on different chromosomes. The regulation of *Hox* genes is controlled by shared, distant regulatory regions. Moreover, the epigenetic state and chromatin organization of the *Hox* clusters determine the function of regulatory elements in the regulation of the *Hox* genes [39, 40]. The regulation of *HoxD* cluster during limb development has been shown to be tightly controlled by a collection of regulatory elements distributed over two gene deserts (a regulatory archipelago) on either side of the *HoxD* cluster. Through conformational changes in the *HoxD* locus, these regulatory elements are brought together to regulate

HoxD gene transcription and coordinate the transition from early to late limb development [41–43].

The examples of the *Irx* and *Hox* gene clusters provide a conceptual framework for co-regulation by shared *cis*-regulatory elements in the locus or even at long distance. It has been proposed that the structural stability of these clusters throughout evolution is maintained by the sharing of conserved regulatory elements by the genes within the cluster [44]. More recently, other loci harboring clustered paralogous genes that are functionally important for heart development and function have come to our attention, including *Tbx3–Tbx5*, *Scn5a–Scn10a* and *Nppa–Nppb*, and have provided insights into the role of structure and composition of the chromatin in genomic function and gene transcription [8, 45, 46].

Spatial and functional organization of *Nppa–Nppb* cluster

With the development of new technologies, different approaches are being used to study loci with respect to their regulatory landscapes of gene loci. These include functional testing of regulatory elements [enhancer and bacterial artificial chromosome (BAC) transgenesis], chromosome conformation capturing, analysis of epigenetic states (ChIP-seq, etc.), and have improved our understanding of the regulatory domains controlling the *Nppa–Nppb* cluster [8, 13].

In gene clusters such as *Irx* and *Hox*, the promoters and their shared distal regulatory regions must be brought together physically in order to regulate transcriptional activity. In general, regulatory elements find their target genes within topologically associating domains (TADs). TADs are chromosomal regions, typically about 1 Mbp in size, within which sequences preferentially contact each other. They are separated by boundary regions for CCCTC-binding factor (CTCF) binding sites [47–49]. It has been established that chromatin loops direct enhancers to target genes, thereby creating a three-dimensional regulatory landscape [25, 50, 51]. High-resolution chromatin conformation capturing (4C) revealed that the intergenomic interactions of the *Nppa–Nppb* cluster are confined to a domain between the two closest CTCF sites, which is a stretch of approximately 60 kbp [8]. Notably, the chromatin conformation of *Nppa* and *Nppb* differs only little between heart tissue and other tissues, indicating it is permissive, existing in a pre-formed 3D conformation, and not instructive and cell-type dependent [8, 25]. This phenomenon of pre-formed chromatin loops has been demonstrated for other loci as well, including the *Tbx3–Tbx5* cluster [52].

Although the exact role of the CTCF sites in *Nppa–Nppb* regulation has yet to be investigated, it is thought that CTCF sites maintain the stability of the regulatory domain.

Previously it has been described that deletion of CTCF sites in the *Hox* gene clusters (*HoxA* and *HoxD*) disrupted the chromatin conformation and altered the regulatory and transcriptional activities in the TADs [53, 54]. Similarly, changing the orientation of a CTCF site influences DNA-looping interactions, consequently leading to transcriptional misregulation [54, 55]. Recent studies of the functional role of CTCF in chromatin folding and transcriptional regulation describe that CTCF is indeed required for the formation and maintenance of loops between CTCF target sites and architecture of TADs at the genomic level [49, 56, 57]. Conditional depletion of CTCF in mouse embryonic stem cells caused insulation defects at most TAD boundaries and abrogation of chromatin loops between CTCF sites. This resulted in altered enhancer–promoter interactions across the DNA region leading to upregulation of a subset of genes that were previously insulated from neighboring regulatory elements. In addition, it has been suggested that CTCF might also have a direct impact on transcriptional regulation independent of loops and chromatin folding. CTCF sites were often found near transcription start site and were mostly in direct orientation with transcription of the downregulated genes prior to CTCF depletion. In contrast, CTCF depletion did not affect genomic compartments. Restoring CTCF levels reversed the chromatin interactome to its normal state [57].


The accessibility of chromatin relies on structural features, which is tightly controlled by epigenetic processes including DNA methylation, histone modifications and ATP-dependent chromatin remodeling. Particular epigenetic mechanisms are associated with active promoters and *cis*-regulatory elements. In adult cardiomyopathy, including cardiac hypertrophy and heart failure, epigenetic changes such as histone acetylation and methylation are observed in response to cardiac stress. This can contribute to transcriptional reprogramming in the heart and changes in cardiac gene expression [58]. Genome-wide analysis of the epigenetic signature of hypertrophied hearts of mice showed that multiple genes implicated in hypertrophic cardiomyopathy and associated enhancers are modified through histone-3 lysine-27 acetylation (H3K27ac), a modification associated with activation [59]. In patients with heart failure, reactivation of *NPPA* and *NPPB* is correlated with demethylation of H3K9 at their promoter regions, although a modest increase in H3K27ac could also be observed [60]. The cofactor p300, important in acetylation of histones, promotes cardiac remodeling (e.g. left ventricular dilation) in infarcted mouse hearts through interaction with transcription factor Gata4 [61]. Furthermore, p300 is found to be recruited to the *Nppa* and *Nppb* promoter, which is associated with increased histone acetylation such as H3K27ac [62]. Within the *Nppa–Nppb* regulatory domain, physical interactions are found between *cis*-regulatory regions and the

promoters of *Nppa* and *Nppb*. These regulatory sequences function to control either developmental or stress-responsive expression of *Nppa* and *Nppb*. Analysis of the distribution of H3K27ac and RNA polymerase II (Pol II) across the *Nppa*–*Nppb* locus revealed that epigenetic signatures within the regulatory domain change during cardiac stress. During pressure overload-induced cardiac hypertrophy in mice, H3K27ac is enriched near and at the promoters of *Nppa* and *Nppb*, whereas Pol II occupation, associated with active promoters and enhancers, changed much less. Even though no significant change in Pol II occupation has been observed, both promoters may still be involved in stress-induced expression of *Nppa* and *Nppb*. In the conserved upstream regulatory region that is associated with fetal expression of *Nppa*, the levels of H3K27ac and Pol II are decreased upon stress [7, 8, 63]. It should be noted that in the normal adult heart, this regulatory region is already highly occupied by H3K27ac and presumably maintains *Nppb* expression after birth (Fig. 1a) [8, 59].

Regulation of the *Nppa*–*Nppb* gene cluster during development and hypertrophy

Genome-wide association studies have found a correlation between genetic variants identified in the *NPPA*–*NPPB* locus and the levels of natriuretic peptides in blood of patients with cardiac dysfunction. A variant (rs5065) in the coding region of *NPPA* [64] and an intronic variant (rs1023252) in *CLCN6* [65] are associated with NT-pro-BNP levels in severe heart failure patients. Furthermore, genetic variants identified upstream and downstream of *NPPB* has proven to significantly affect levels of BNP [66]. Together, this suggest that variants in the *NPPA*–*NPPB* regulatory domain (and in linkage disequilibrium with the reported variants) influence regulatory DNA function. Genetic variants associated with blood pressure and hypertension at the *AGTRAP*–*PLOD1* locus are suggested to influence the expression of multiple genes, including *NPPA* and *NPPB*, within this region [67]. These genetic variants are in linkage disequilibrium with the *NPPA*–*NPPB* regulatory domain and, therefore, may only report the presence of variants influencing regulatory DNA function of *NPPA* and *NPPB* during disease. Indeed,

Fig. 1 The regulatory landscape of the *Nppa*–*Nppb* locus. **a** Developmental and stress response regulatory regions of *Nppa* and *Nppb* are located within a 60 kbp domain between two CTCF sites arranged in a convergent orientation [49, 91]. Purple, shared regulatory regions of *Nppa*/*Nppb*; green, regulatory regions of *Nppa*; red, regulatory regions of *Nppb*. Gray bars, BAC clones. Displaying EMERGE track for heart and H3K27ac track for mouse cardiomyocytes [92, 93]. **b** *Nppa* and *Nppb* are regulated by different regulatory elements during stress. The *Nppa* promoter interacts with *Nppb* promoter and several distal and proximal regulatory elements. Stress-induced expression of *Nppb* is regulated by an upstream regulatory region and the *Nppa*/*Nppb* promoters



it has been reported that genetic variants positioned within the regulatory domain of *NPPA*–*NPPB* locus potentially affect gene expression by a yet undefined mechanism [68]. The biological and clinical relevance of *Nppa* and *Nppb* is probably the major reason the transcriptional regulation of these genes has been the subject of several studies [7, 8, 22–24]. *Nppa* and *Nppb* are reactivated in the stressed myocardium as part of an induction of a “fetal gene program”. The question remained whether the transcriptional mechanisms involved in hypertrophic stress induction are the same as those governing the fetal gene program. Previously, it has been suggested that the proximal *Nppa* promoter mediates the developmental expression pattern of *Nppa*, although later it was found that its capacity to drive ventricular expression was largely absent [7, 22, 69, 70]. Furthermore, this promoter is inducible in cell culture systems, but not sufficient for stress-induced *Nppa* expression in vivo, suggesting the involvement of other distal regulatory elements [7, 22]. Furthermore, ventricular expression of *Nppa* was found to be driven by distal sequences, whereas stress induction required more proximal sequences, demonstrating that the transcriptional mechanisms driving fetal expression and stress-induced expression are different [7].

The *Nppa* promoter has been used as a model for understanding transcriptional gene regulation during cardiac development [9, 69, 71, 72]. It was thought that the *Nppa* promoter drives embryonic and fetal *Nppa* expression in the atria and ventricles but different fragment sizes of the promoter could not recapitulate the correct ventricular expression [7, 70]. Several regulatory elements that lie upstream of the proximal *Nppa* promoter region appeared to be involved in the ventricular expression of *Nppa* during development. Two reporter BAC clones with 85 kbp of overlapping sequences (BAC336-*EGFP* and BAC337-*EGFP*) (Fig. 1a) covering the *Nppa*–*Nppb* locus were used in an attempt to define the distal regulatory regions that control the pre- and postnatal expression of *Nppa* in the ventricles (Fig. 1a). BAC337-*EGFP* was shown to lack the regulatory sequences necessary for *Nppa* ventricular activity, and unique sequences located in BAC336-*EGFP* (– 141 to – 27 kbp relative to *Nppa*) drove *Nppa*-like expression patterns during development [7]. The potential of this regulatory region (– 141 to – 27 kbp relative to *Nppa*) in mediating the developmental expression of *Nppa* was further supported by analysis of Nkx2–5 occupancy and function in vivo. The transcription factor Nkx2–5 has a major role in the regulation of gene expression in the developing heart. In vivo screening of the regulatory elements within the *Nppa*–*Nppb* locus in inducible Nkx2–5 knockout mice showed a diminished expression in the heart, indicating an essential role of Nkx2–5 in the regulation of *Nppa*. Indeed, 3C analysis showed that these regulatory elements enriched for Nkx2–5 interact with the *Nppa* promoter. However, stress-induced

expression of *Nppa* did not depend on Nkx2–5 transcriptional regulation [23]. Further studies on BAC336-*EGFP* and BAC337-*EGFP* revealed that both were able to induce reporter gene expression upon hypertrophic stress. This demonstrates that both BAC clones contain regulatory sequences that mediate stress-induced *Nppa* expression. These sequences are thought to be located in the overlapping 85 kbp region and downstream of *Nppa* (Fig. 1a) [7]. Analysis of both BAC clones revealed that the distal regulatory region is responsible for *Nppa* expression in the embryonic/fetal and adult heart, whereas the proximal regulatory region is required for stress-induced *Nppa* expression.

The development and stress-induced regulatory elements of *Nppb* were less well described compared to *Nppa*. There is evidence that the promoter constitutively drives weak *Nppb* expression in the normal and stressed heart [73, 74]. As described below, later studies showed other regulatory elements within the *Nppa*–*Nppb* locus are required [8].

Recently, a more extensive characterization of the spatial and functional organization of the *Nppa*–*Nppb* cluster in vivo has been provided. Based on H3K27ac and Pol2 ChIP-seq data, heart-specific regulatory regions were defined in the *Nppa*–*Nppb* locus (Fig. 1a), which were functionally tested in a transgenic mouse model carrying a BACs with two modifications. The function of the *Nppa*–*Nppb* cluster can be monitored simultaneously for both *Nppa* and *Nppb* due to the insertion of the *Luciferase* and *Katushka* genes at the translation start sites of these genes, respectively, within the BAC. Both reporter genes recapitulate the tissue-specific and developmental pattern of expression and stress response of endogenous *Nppa* and *Nppb* [8, 13]. Analyses of the BAC transgenic mice showed that developmental expression of *Nppa* and *Nppb* is mediated by shared *cis*-regulatory elements located approximately 27 kbp upstream of *Nppa* (Fig. 1a). This regulatory region, roughly 10 kbp, is enriched for epigenetic features including heart-specific DNaseI hypersensitivity sites and histone modifications, and binding sites for various cardiac transcription factors (e.g. Nkx2–5 and Gata4). Furthermore, this regulatory region is being described as a “super enhancer” [75, 76]. According to the conformation of the *Nppa*–*Nppb* locus, this region contacts the promoters of both genes, suggesting that regulatory elements within this region drive the fetal ventricular expression of *Nppa* and *Nppb*. Furthermore, this region might also contain regulatory elements involved in *Nppb* expression during hypertrophic stress in the adult heart (Fig. 1a, b) A 650-bp fragment located in the same region was implicated in stress-induced *Nppa* expression [24]; however, the BAC transgenesis study indicates it may be involved in *Nppb* regulation. This finding is further supported by analysis of transgenic lines with BAC337 that lacks this region, in which strong *EGFP* expression (reporting for *Nppa*) was observed in stressed ventricles [7, 8, 24].

However, it is uncertain whether this 650 bp fragment is involved in induction during hypertrophy as no response has been observed in vitro after stimulation with phenylephrine (PE) or hypertrophic stress in transgenic mice with this fragment (Sergeeva, unpublished data).

Which particular regulatory elements drive stress-induced *Nppa* expression remains unresolved. There are indications that the *Nppb* promoter might be involved; its deletion within the double reporter BAC rendered *Luciferase/Nppa* non-responsive to hypertrophy. However, the *Nppb* promoter alone was not sufficient to drive *Nppa* expression upon hypertrophic stress. The *Nppb* promoter is necessary for the embryonic/fetal and adult expression of *Nppb* itself, but not required for hypertrophic induction. Nevertheless, the *Nppb* promoter drives *Luciferase* expression in rat ventricular cardiomyocytes after PE stimulation. Together, these data suggest that the *Nppb* promoter is part of a complex of proximal and distal regulatory elements, all required in vivo, whereas several of these elements may drive stress-responsive expression when tested outside their endogenous context (Fig. 1a) [8].

***Nppa*–*Nppb* cluster locus containing conserved regulatory elements activated during zebrafish heart regeneration**

Myocardial infarction causes loss of heart muscle. In contrast to lower vertebrates like fish and amphibians, the mammalian heart has a highly insufficient capacity to regenerate and restore this muscle tissue. Studies on zebrafish heart

regeneration have demonstrated through genetic lineage tracing that proliferating cardiomyocytes are the source of the newly formed cardiomyocytes. These (adult) cardiomyocytes have first undergone dedifferentiation, which is characterized by disassembly of sarcomeric structures and re-expression of genes such as *Gata4* involved in heart development and *Nppa/Nppb* [77–80]. Recently it has been shown that a similar regenerative response is found in neonatal mice, in which the cardiomyocytes retain for a short period of time the ability to proliferate [81]. Cardiomyocyte renewal in adult mice (and humans) is very limited under normal conditions with a less turnover rate of less than 1 percent per year [82, 83]. In adult mouse myocardial infarction models, cardiomyocyte proliferation has been observed, but too low to regenerate the injured heart [82, 84, 85].

During fetal and neonatal development, cardiomyocytes rapidly proliferate and, therefore, the myocardium can regenerate upon injury. From studies aimed at understanding the regulation of cardiomyocyte proliferation and regeneration it has been suggested that cardiomyocyte-intrinsic programs can promote these regenerative processes upon cardiac injury [86]. Exploiting the transcriptional dynamics during zebrafish heart regeneration suggest that these transcriptional regulatory mechanisms recapitulate the fetal gene program [79, 87]. Furthermore, the spatial gene expression profile of a cryo-injured zebrafish heart revealed the transcriptional activation of *nppa* and *nppb* in a district region (the border zone) within the heart where also regeneration occurs (Fig. 2a) [80]. Interestingly, reactivation of *Nppa* and *Nppb* is also restricted to the border zone of an injured mouse heart (Fig. 2b) [10]. This raises the question




Fig. 2 Expression of zebrafish *nppa* and *nppb* and of mouse *Nppa* mRNA in sections of an injured zebrafish and mouse heart. **a, b** Both fetal genes are reactivated in the border zone (bz) after cryo-injury and myocardial infarction, respectively [10, 80]

whether conserved stress responsive regulatory elements for *Nppa/nppa* and *Nppb/nppb* exists in the mouse and zebrafish heart that are associated with an intrinsic mechanism for cardiomyocyte renewal. Only recently, evidence suggests that conserved regulatory elements may indeed be present that can induce the transcriptional programs for heart regeneration upon tissue damage. In the zebrafish *leptin b* locus a distal regulatory element has been identified that directs gene expression after injury, including fin amputation and cryo-injury [88]. This regulatory element and response of leptin are not conserved in the mouse, and the regulatory element is active in the endocardium. Nevertheless, the leptin-linked regulatory element was activated in an injured neonatal mouse heart. Furthermore, the leptin-linked regulatory element could activate *Nrg1/ErbB2/ErbB4* pathway to promote cardiomyocyte proliferation after re-sectioning of the zebrafish heart [88]. Recent histone H3.3 replacement profiling of regenerative zebrafish hearts uncovered thousands of putative regenerative-responsive enhancers in the fish genome [89]. These findings raise the possibility that the *Nppa–Nppb* cluster might also harbor conserved regulatory elements which are activated after cardiac injury that can initiate transcriptional programs for dedifferentiation and proliferation of adult cardiomyocytes. Studying the transcriptional regulation of *Nppa* and *Nppb* during disease may uncover these regulatory elements.

Conclusion and future perspectives

The natriuretic peptides ANF and BNP are widely used as biomarkers in various cardiovascular diseases in clinical settings. Studies of the structure and function of the *Nppa–Nppb* cluster has provided novel insights into the transcriptional regulatory mechanisms of *Nppa* and *Nppb* expression during heart development and disease. The transcriptional regulation of *Nppa* and *Nppb* has proven to be complex. *Nppa*, which is highly expressed during ventricular stress, is controlled by several different proximal and distal regulatory elements, including the *Nppb* promoter, to regulate its dynamic expression in the embryonic/fetal and adult heart. *Nppb* expression relies on the interaction of its promoter and a conserved large distal regulatory region, classified as a “super enhancer”. Moreover, the *Nppa–Nppb* cluster shares (developmental) enhancers found in the super enhancer region. The *Nppa–Nppb* gene cluster provides a conceptual framework for understanding gene cluster function and enhancer sharing that likely applies to other loci that harbor clustered genes. Other interesting gene clusters such as *Tbx3–Tbx5* [45], *Scn5a–Scn10a* [46], *Kcne1–Kcne2*, *Kcnj2–Kcnj16*, *HoxA* and *HoxB* [90] are being studied or have yet to be studied with respect to transcriptional (co-) regulation and genomic function in the heart. Although the

paradigm of heart regeneration in the mammalian adult heart is being debated, evidence suggests that conserved regulatory elements are activated after cardiac injury, which controls the transcriptional programs for heart regeneration in fish. Therefore, an intriguing question is whether the regulatory elements found in the *Nppa–Nppb* cluster respond to a regenerative mechanism in the stressed myocardium. Future research may focus on the manipulation of the regulatory sequences of the *Nppa–Nppb* locus in vivo by CRISPR/Cas9 genome editing to determine their physiological relevance in the context of hypertrophic stress or ischemic injury. Furthermore, stress response regulatory elements of the mammalian *Nppa–Nppb* cluster can be integrated into the zebrafish genome by site-directed transgene integration to assess whether these sequences are transcriptionally activated during zebrafish heart regeneration. The identification of these conserved regulatory elements can provide tools to drive therapeutic genes that promote adult mammalian heart regeneration.

Acknowledgements This work was supported by CVON HUSTCARE and Foundation Leducq.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Drazner MH (2011) The progression of hypertensive heart disease. *Circulation* 123(3):327–334. <https://doi.org/10.1161/CIRCULATIONAHA.108.845792>
2. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL (2002) Heart failure after myocardial infarction: a review. *Am J Med* 113(4):324–330
3. Izumo S, Nadal-Ginard B, Mahdavi V (1988) Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. *Proc Natl Acad Sci USA* 85:339–343
4. Chien KR, Knowlton KU, Zhu H, Chien S (1991) Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. *FASEB J* 5:3037–3046
5. Komuro I, Yazaki Y (1993) Control of cardiac gene expression by mechanical stress. *Annu Rev Physiol* 55:55–75. <https://doi.org/10.1146/annurev.ph.55.030193.000415>
6. Kuwahara K, Nishikimi T, Nakao K (2012) Transcriptional regulation of the fetal cardiac gene program. *J Pharmacol Sci* 119(3):198–203
7. Horsthuis T, Houweling AC, Habets PEMH, de Lange FJ, el Azzouzi H, Clout DEW, Moorman AFM, Christoffels VM (2008) Distinct regulation of developmental and heart disease induced atrial natriuretic factor expression by two separate distal sequence. *Circ Res* 102:849–859

8. Sergeeva IA, Hooijkaas IB, Ruijter JM, van der Made I, de Groot NE, van de Werken HJ, Creemers EE, Christoffels VM (2016) Identification of a regulatory domain controlling the *Nppa*–*Nppb* gene cluster during heart development and stress. *Development*. <https://doi.org/10.1242/dev.132019>
9. Houweling AC, van Borren MM, Moorman AFM, Christoffels VM (2005) Expression and regulation of the atrial natriuretic factor encoding gene *Nppa* during development and disease. *Cardiovasc Res* 67:583–593
10. Sergeeva I, Christoffels VM (2013) Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. *Biochim Biophys Acta*. <https://doi.org/10.1016/j.bbadis.2013.07.003>
11. Cameron VA, Aitken GD, Ellmers LJ, Kennedy MA, Espiner EA (1996) The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: temporal changes in embryos and placenta. *Endocrinology* 137(3):817–824
12. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A, Faruq NS, Karmazyn M (2011) Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. *Circ Heart Fail* 4(1):79–88. <https://doi.org/10.1161/CIRCHEARTFAILURE.110.957969>
13. Sergeeva IA, Hooijkaas IB, van der Made I, Jong WM, Creemers EE, Christoffels VM (2013) A transgenic mouse model for the simultaneous monitoring of ANF and BNP gene activity during heart development and disease. *Cardiovasc Res*. <https://doi.org/10.1093/cvr/cvt228>
14. Troughton R, Michael Felker G, Januzzi JL Jr (2014) Natriuretic peptide-guided heart failure management. *Eur Heart J* 35(1):16–24. <https://doi.org/10.1093/eurheartj/eh463>
15. de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A (2012) Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. *Am Heart J* 163(5):821–828. <https://doi.org/10.1016/j.ahj.2012.03.004>
16. Christoffels VM, Habets PEMH, Franco D, Campione M, de Jong F, Lamers WH, Bao ZZ, Palmer S, Biben C, Harvey RP, Moorman AFM (2000) Chamber formation and morphogenesis in the developing mammalian heart. *Dev Biol* 223:266–278
17. Bruneau BG (2011) Atrial natriuretic factor in the developing heart: a signpost for cardiac morphogenesis. *Can J Physiol Pharmacol* 89(8):533–537. <https://doi.org/10.1139/y11-051>
18. Kathiriyia IS, Nora EP, Bruneau BG (2015) Investigating the transcriptional control of cardiovascular development. *Circ Res* 116(4):700–714. <https://doi.org/10.1161/CIRCRESAHA.116.302832>
19. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, Porter JG (1989) Human and canine gene homologs of porcine brain natriuretic peptide. *Biochem Biophys Res Commun* 165(2):650–658
20. Wu JP, Kovacic-Milivojevic B, Lapointe MC, Nakamura K, Gardner DG (1991) *cis*-Active determinants of cardiac-specific expression in the human atrial natriuretic peptide gene. *Mol Endocrinol* 5(9):1311–1322. <https://doi.org/10.1210/mend-5-9-1311>
21. Inoue K, Sakamoto T, Yuge S, Iwatani H, Yamagami S, Tsutsumi M, Hori H, Cerra MC, Tota B, Suzuki N, Okamoto N, Takei Y (2005) Structural and functional evolution of three cardiac natriuretic peptides. *Mol Biol Evol* 22(12):2428–2434. <https://doi.org/10.1093/molbev/msi243>
22. Knowlton KU, Rockman HA, Itani M, Vovan A, Seidman CE, Chien KR (1995) Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. *J Clin Invest* 96:1311–1318
23. Warren SA, Terada R, Briggs LE, Cole-Jeffrey CT, Chien WM, Seki T, Weinberg EO, Yang TP, Chien MT, Bungert J, Kasahara H (2011) Differential role of *Nkx2–5* in activation of the ANF gene in developing vs. failing heart. *Mol Cell*. <https://doi.org/10.1126/SCIENCE.1211111>
24. Matsuoka K, Asano Y, Higo S, Tsukamoto O, Yan Y, Yamazaki S, Matsuzaki T, Kioka H, Kato H, Uno Y, Asakura M, Asanuma H, Minamino T, Aburatani H, Kitakaze M, Komuro I, Takashima S (2014) Noninvasive and quantitative live imaging reveals a potential stress-responsive enhancer in the failing heart. *FASEB J* 28(4):1870–1879. <https://doi.org/10.1096/fj.13-245522>
25. de Laat W, Duboule D (2013) Topology of mammalian developmental enhancers and their regulatory landscapes. *Nature* 502(7472):499–506. <https://doi.org/10.1038/nature12753>
26. Sanyal A, Lajoie BR, Jain G, Dekker J (2012) The long-range interaction landscape of gene promoters. *Nature* 489(7414):109–113. <https://doi.org/10.1038/nature11279>
27. Spitz F, Furlong EE (2012) Transcription factors: from enhancer binding to developmental control. *Nat Rev Genet* 13(9):613–626. <https://doi.org/10.1038/nrg3207>
28. Inoue K, Naruse K, Yamagami S, Mitani H, Suzuki N, Takei Y (2003) Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. *Proc Natl Acad Sci USA* 100(17):10079–10084
29. Takei Y, Inoue K, Trajanovska S, Donald JA (2011) B-type natriuretic peptide (BNP), not ANP, is the principal cardiac natriuretic peptide in vertebrates as revealed by comparative studies. *Gen Comp Endocrinol* 171(3):258–266. <https://doi.org/10.1016/j.ygcen.2011.02.021>
30. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhilber ME, Field LJ, Ross J Jr, Chien KR (1991) Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. *Proc Natl Acad Sci USA* 88(18):8277–8281
31. Peters T, Dildrop R, Ausmeier K, R  ther U (2000) Organization of mouse Iroquois homeobox genes in two clusters suggests a conserved regulation and function in vertebrate development. *Genome Res* 10(10):1453–1462
32. Houweling AC, Dildrop R, Peters T, Mummenhoff J, Moorman AFM, R  ther U, Christoffels VM (2001) Gene and cluster-specific expression of the *Iroquois* family members during mouse development. *Mech Dev* 107:169–174
33. Kim KH, Rosen A, Bruneau BG, Hui CC, Backx PH (2012) Iroquois homeodomain transcription factors in heart development and function. *Circ Res* 110(11):1513–1524. <https://doi.org/10.1161/CIRCRESAHA.112.265041>
34. Christoffels VM, Keijsers AGM, Houweling AC, Clout DEW, Moorman AFM (2000) Patterning the embryonic heart: Identification of five mouse Iroquois homeobox genes in the developing heart. *Dev Biol* 224:263–274
35. Tena JJ, Alonso ME, Calle-Mustienes E, Splinter E, de Laat W, Manzanares M, Gomez-Skarmeta JL (2011) An evolutionarily conserved three-dimensional structure in the vertebrate *Irx* clusters facilitates enhancer sharing and coregulation. *Nat Commun* 2:310. <https://doi.org/10.1038/ncomms1301>
36. Mallo M, Wellik DM, Deschamps J (2010) Hox genes and regional patterning of the vertebrate body plan. *Dev Biol* 344(1):7–15. <https://doi.org/10.1016/j.ydbio.2010.04.024>
37. Wellik DM (2007) Hox patterning of the vertebrate axial skeleton. *Dev Dyn* 236(9):2454–2463. <https://doi.org/10.1002/dvdy.21286>
38. Zakany J, Duboule D (2007) The role of Hox genes during vertebrate limb development. *Curr Opin Genet Dev* 17(4):359–366. <https://doi.org/10.1016/j.gde.2007.05.011>
39. Garcia-Fernandez J (2005) The genesis and evolution of homeobox gene clusters. *Nat Rev Genet* 6(12):881–892. <https://doi.org/10.1038/nrg1723>

40. Tschopp P, Duboule D (2011) A regulatory ‘landscape effect’ over the HoxD cluster. *Dev Biol* 351(2):288–296. <https://doi.org/10.1016/j.ydbio.2010.12.034>
41. Montavon T, Soshnikova N, Mascrez B, Joye E, Thevenet L, Splinter E, de Laat W, Spitz F, Duboule D (2011) A regulatory archipelago controls Hox genes transcription in digits. *Cell* 147(5):1132–1145. <https://doi.org/10.1016/j.cell.2011.10.023>
42. Tarchini B, Duboule D (2006) Control of Hoxd genes’ collinearity during early limb development. *Dev Cell* 10(1):93–103. <https://doi.org/10.1016/j.devcel.2005.11.014>
43. Andrey G, Montavon T, Mascrez B, Gonzalez F, Noordermeer D, Leleu M, Trono D, Spitz F, Duboule D (2013) A switch between topological domains underlies HoxD genes collinearity in mouse limbs. *Science* 340(6137):1234167. <https://doi.org/10.1126/science.1234167>
44. Spitz F, Duboule D (2008) Global control regions and regulatory landscapes in vertebrate development and evolution. *Adv Genet* 61:175–205. [https://doi.org/10.1016/S0065-2660\(07\)00006-5](https://doi.org/10.1016/S0065-2660(07)00006-5)
45. van Weerd JH, Badi I, van den Boogaard M, Stefanovic S, van de Werken HJ, Gomez-Velazquez M, Badia-Careaga C, Manzanares M, de Laat W, Barnett P, Christoffels VM (2014) A large permissive regulatory domain exclusively controls Tbx3 expression in the cardiac conduction system. *Circ Res* 115:432–441. <https://doi.org/10.1161/CIRCRESAHA.115.303591>
46. van den Boogaard M, Smemo S, Burnicka-Turek O, Arnolds DE, van de Werken HJ, Klous P, McKean D, Muehlschlegel JD, Moosmann J, Toka O, Yang XH, Koopmann TT, Adriaens ME, Bezzina CR, de Laat W, Seidman C, Seidman JG, Christoffels VM, Noreaga MA, Barnett P, Moskowitz IP (2014) A common genetic variant within SCN10A modulates cardiac SCN5A expression. *J Clin Investig* 124(4):1844–1852. <https://doi.org/10.1172/JCI73140>
47. Nora EP, Dekker J, Heard E (2013) Segmental folding of chromosomes: a basis for structural and regulatory chromosomal neighborhoods? *Bioessays* 35(9):818–828. <https://doi.org/10.1002/bies.201300040>
48. Ong CT, Corces VG (2014) CTCF: an architectural protein bridging genome topology and function. *Nat Rev Genet* 15(4):234–246. <https://doi.org/10.1038/nrg3663>
49. de Wit E, Vos ES, Holwerda SJ, Valdes-Quezada C, Verstegen MJ, Teunissen H, Splinter E, Wijchers PJ, Krijger PH, de Laat W (2015) CTCF binding polarity determines chromatin looping. *Mol Cell* 60(4):676–684. <https://doi.org/10.1016/j.molcel.2015.09.023>
50. Krijger PH, de Laat W (2016) Regulation of disease-associated gene expression in the 3D genome. *Nat Rev Mol Cell Biol* 17(12):771–782. <https://doi.org/10.1038/nrm.2016.138>
51. Schwarzer W, Spitz F (2014) The architecture of gene expression: integrating dispersed *cis*-regulatory modules into coherent regulatory domains. *Curr Opin Genet Dev* 27:74–82. <https://doi.org/10.1016/j.gde.2014.03.014>
52. van Weerd JH, Koshiba-Takeuchi K, Kwon C, Takeuchi JK (2011) Epigenetic factors and cardiac development. *Cardiovasc Res* 91(2):203–211. <https://doi.org/10.1093/cvr/cvr138>
53. Narendra V, Rocha PP, An D, Raviram R, Skok JA, Mazzoni EO, Reinberg D (2015) CTCF establishes discrete functional chromatin domains at the Hox clusters during differentiation. *Science* 347(6225):1017–1021. <https://doi.org/10.1126/science.1262088>
54. Lupianez DG, Kraft K, Heinrich V, Krawitz P, Brancati F, Kloppock E, Horn D, Kayserili H, Opitz JM, Laxova R, Santos-Simarro F, Gilbert-Dussardier B, Wittler L, Borschiwer M, Haas SA, Osterwalder M, Franke M, Timmermann B, Hecht J, Spielmann M, Visel A, Mundlos S (2015) Disruptions of topological chromatin domains cause pathogenic rewiring of gene–enhancer interactions. *Cell* 161(5):1012–1025. <https://doi.org/10.1016/j.cell.2015.04.004>
55. Guo Y, Xu Q, Canzio D, Shou J, Li J, Gorkin DU, Jung I, Wu H, Zhai Y, Tang Y, Lu Y, Wu Y, Jia Z, Li W, Zhang MQ, Ren B, Krainer AR, Maniatis T, Wu Q (2015) CRISPR inversion of CTCF sites alters genome topology and enhancer/promoter function. *Cell* 162(4):900–910. <https://doi.org/10.1016/j.cell.2015.07.038>
56. Phillips JE, Corces VG (2009) CTCF: master weaver of the genome. *Cell* 137(7):1194–1211. <https://doi.org/10.1016/j.cell.2009.06.001>
57. Nora EP, Goloborodko A, Valton AL, Gibcus JH, Uebersohn A, Abdennur N, Dekker J, Mirny LA, Bruneau BG (2017) Targeted degradation of CTCF decouples local insulation of chromosome domains from genomic compartmentalization. *Cell* 169(5):930 e922–944 e922. <https://doi.org/10.1016/j.cell.2017.05.004>
58. Mahmoud SA, Poizat C (2013) Epigenetics and chromatin remodeling in adult cardiomyopathy. *J Pathol* 231(2):147–157. <https://doi.org/10.1002/path.4234>
59. Papatit R, Cattaneo P, Kunderfranco P, Greco C, Carullo P, Guffanti A, Vigano V, Stirparo GG, Latronico MV, Hasenfuss G, Chen J, Condorelli G (2013) Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. *Proc Natl Acad Sci USA* 110(50):20164–20169. <https://doi.org/10.1073/pnas.1315155110>
60. Hohl M, Wagner M, Reil JC, Muller SA, Tauchnitz M, Zimmer AM, Lehmann LH, Thiel G, Bohm M, Backs J, Maack C (2013) HDAC4 controls histone methylation in response to elevated cardiac load. *J Clin Investig* 123(3):1359–1370. <https://doi.org/10.1172/JCI61084>
61. Miyamoto S, Kawamura T, Morimoto T, Ono K, Wada H, Kawase Y, Matsumori A, Nishio R, Kita T, Hasegawa K (2006) Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. *Circulation* 113(5):679–690. <https://doi.org/10.1161/CIRCULATIONAHA.105.585182>
62. Mathiyalagan P, Chang L, Du XJ, El-Osta A (2010) Cardiac ventricular chambers are epigenetically distinguishable. *Cell Cycle* 9(3):612–617. <https://doi.org/10.4161/cc.9.3.10612>
63. Sayed D, He M, Yang Z, Lin L, Abdellatif M (2013) Transcriptional regulation patterns revealed by high resolution chromatin immunoprecipitation during cardiac hypertrophy. *J Biol Chem* 288(4):2546–2558. <https://doi.org/10.1074/jbc.M112.429449>
64. Vassalle C, Andreassi MG, Prontera C, Fontana M, Zyw L, Passino C, Emdin M (2007) Influence of Scf and natriuretic peptide (NP) clearance receptor polymorphisms of the NP system on NP concentration in chronic heart failure. *Clin Chem* 53(11):1886–1890. <https://doi.org/10.1373/clinchem.2007.088302>
65. Del Greco MF, Pattaro C, Luchner A, Pichler I, Winkler T, Hicks AA, Fuchsberger C, Franke A, Melville SA, Peters A, Wichmann HE, Schreiber S, Heid IM, Krawczak M, Minelli C, Wiedermann CJ, Pramstaller PP (2011) Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR–CLCN6–NPPA–NPPB gene cluster. *Hum Mol Genet* 20(8):1660–1671. <https://doi.org/10.1093/hmg/ddr035>
66. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL (2007) Genetic variation in the B-type natriuretic peptide pathway affects BNP levels. *Cardiovasc Drugs Ther* 21(1):55–62. <https://doi.org/10.1007/s10557-007-6007-5>
67. Flister MJ, Tsaih SW, O’Meara CC, Endres B, Hoffman MJ, Geurts AM, Dwinell MR, Lazar J, Jacob HJ, Moreno C (2013) Identifying multiple causative genes at a single GWAS locus. *Genome Res* 23(12):1996–2002. <https://doi.org/10.1101/gr.160283.113>
68. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler

- NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ (2009) Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. *Nat Genet* 41(3):348–353. <https://doi.org/10.1038/ng.328>
69. Habets PEMH, Moorman AFM, Clout DEW, van Roon MA, Lingbeek M, Lohuizen M, Campione M, Christoffels VM (2002) Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: implications for cardiac chamber formation. *Genes Dev* 16:1234–1246
70. de Lange FJ, Moorman AFM, Christoffels VM (2003) Atrial cardiomyocyte-specific expression of Cre recombinase driven by an Nppa gene fragment. *Genesis* 37:1–4
71. Nemer G, Nemer M (2001) Regulation of heart development and function through combinatorial interactions of transcription factors. *Ann Med* 33(9):604–610
72. Temsah R, Nemer M (2005) Gata factors and transcriptional regulation of cardiac natriuretic peptide genes. *Regul Pept* 128:177–185
73. Majalahti T, Suo-Palosaari M, Sarman B, Hautala N, Pikkarainen S, Tokola H, Vuolteenaho O, Wang J, Paradis P, Nemer M, Ruskoaho H (2007) Cardiac BNP gene activation by angiotensin II in vivo. *Mol Cell Endocrinol* 273(1–2):59–67. <https://doi.org/10.1016/j.mce.2007.05.003>
74. He Q, Wang D, Yang XP, Carretero OA, LaPointe MC (2001) Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. *Am J Physiol Heart Circ Physiol* 280(1):H368–H376
75. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA, Young RA (2013) Super-enhancers in the control of cell identity and disease. *Cell* 155(4):934–947. <https://doi.org/10.1016/j.cell.2013.09.053>
76. Wei Y, Zhang S, Shang S, Zhang B, Li S, Wang X, Wang F, Su J, Wu Q, Liu H, Zhang Y (2016) SEA: a super-enhancer archive. *Nucleic Acids Res* 44(D1):D172–D179. <https://doi.org/10.1093/nar/gkv1243>
77. Poss KD, Wilson LG, Keating MT (2002) Heart regeneration in zebrafish. *Science* 298(5601):2188–2190
78. Jopling C, Sleep E, Raya M, Marti M, Raya A, Belmonte JC (2010) Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* 464(7288):606–609
79. Kikuchi K, Holdway JE, Werdich AA, Anderson RM, Fang Y, Egnaczyk GF, Evans T, MacRae CA, Stainier DY, Poss KD (2010) Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. *Nature* 464(7288):601–605
80. Wu CC, Kruse F, Vasudevarao MD, Junker JP, Zebrowski DC, Fischer K, Noel ES, Grun D, Berezikov E, Engel FB, van Oudenaarden A, Weidinger G, Bakkers J (2016) Spatially resolved genome-wide transcriptional profiling identifies BMP signaling as essential regulator of zebrafish cardiomyocyte regeneration. *Dev Cell* 36(1):36–49. <https://doi.org/10.1016/j.devcel.2015.12.010>
81. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA (2011) Transient regenerative potential of the neonatal mouse heart. *Science* 331(6020):1078–1080. <https://doi.org/10.1126/science.1200708>
82. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, Wu TD, Guerquin-Kern JL, Lechene CP, Lee RT (2013) Mammalian heart renewal by pre-existing cardiomyocytes. *Nature* 493(7432):433–436. <https://doi.org/10.1038/nature11682>
83. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J (2009) Evidence for cardiomyocyte renewal in humans. *Science* 324(5923):98–102
84. Bersell K, Arab S, Haring B, Kuhn B (2009) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. *Cell* 138(2):257–270
85. Steinhauser ML, Lee RT (2011) Regeneration of the heart. *EMBO Mol Med* 3(12):701–712. <https://doi.org/10.1002/emmm.201100175>
86. Foglia MJ, Poss KD (2016) Building and re-building the heart by cardiomyocyte proliferation. *Development* 143(5):729–740. <http://s://doi.org/10.1242/dev.132910>
87. Gupta V, Gemberling M, Karra R, Rosenfeld GE, Evans T, Poss KD (2013) An injury-responsive gata4 program shapes the zebrafish cardiac ventricle. *Curr Biol* 23(13):1221–1227. <http://s://doi.org/10.1016/j.cub.2013.05.028>
88. Kang J, Hu J, Karra R, Dickson AL, Tornini VA, Nachtrab G, Gemberling M, Goldman JA, Black BL, Poss KD (2016) Modulation of tissue repair by regeneration enhancer elements. *Nature* 532(7598):201–206. <https://doi.org/10.1038/nature17644>
89. Goldman JA, Kuzu G, Lee N, Karasik J, Gemberling M, Foglia MJ, Karra R, Dickson AL, Sun F, Tolstorukov MY, Poss KD (2017) Resolving heart regeneration by replacement histone profiling. *Dev Cell* 40(4):392 e395–404 e395. <https://doi.org/10.1016/j.devcel.2017.01.013>
90. Nolte C, Jinks T, Wang X, Martinez Pastor MT, Krumlauf R (2013) Shadow enhancers flanking the HoxB cluster direct dynamic Hox expression in early heart and endoderm development. *Dev Biol* 383(1):158–173. <https://doi.org/10.1016/j.ydbio.2013.09.016>
91. Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, Sanborn AL, Machol I, Omer AD, Lander ES, Aiden EL (2014) A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* 159(7):1665–1680. <https://doi.org/10.1016/j.cell.2014.11.021>
92. Gilsbach R, Preissl S, Gruning BA, Schnick T, Burger L, Benes V, Wurch A, Bonisch U, Gunther S, Backofen R, Fleischmann BK, Schubeler D, Hein L (2014) Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease. *Nat Commun* 5:5288. <https://doi.org/10.1038/ncomms6288>
93. van Duijvenboden K, de Boer BA, Capon N, Ruijter JM, Christoffels VM (2015) EMERGE: a flexible modelling framework to predict genomic regulatory elements from genomic signatures. *Nucleic Acids Res*. <https://doi.org/10.1093/nar/gkv1144>